AbbVie Inc. vs Assurant, Inc.: Strategic Comparison
Key Differences at a Glance
| Field | AbbVie Inc. | Assurant, Inc. |
|---|---|---|
| Revenue | $61.2B | $12.8B |
| Founded | 2013 | 1892 |
| Employees | 57,000 | 14,800 |
| Market Cap | $451.5B | $10.5B |
| Headquarters | United States | United States |
Quick Stats Comparison
| Metric | AbbVie Inc. | Assurant, Inc. |
|---|---|---|
| Revenue | $61.2B | $12.8B |
| Founded | 2013 | 1892 |
| Headquarters | North Chicago, Illinois | Atlanta, Georgia |
| Market Cap | $451.5B | $10.5B |
| Employees | 57,000 | 14,800 |
AbbVie Inc. Revenue vs Assurant, Inc. Revenue — Year by Year
| Year | AbbVie Inc. | Assurant, Inc. | Leader |
|---|---|---|---|
| 2025 | $61.2B | $12.8B | AbbVie Inc. |
| 2024 | $56.3B | $12.4B | AbbVie Inc. |
| 2023 | $54.3B | $11.9B | AbbVie Inc. |
| 2022 | $58.1B | $11.2B | AbbVie Inc. |
| 2021 | $56.2B | N/A | AbbVie Inc. |
Business Model Breakdown
Overview: AbbVie Inc. vs Assurant, Inc.
This in-depth comparison examines AbbVie Inc. and Assurant, Inc. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching AbbVie Inc. on its own, evaluating Assurant, Inc., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between AbbVie Inc. and Assurant, Inc. is widest.
On the headline numbers, AbbVie Inc. reports annual revenue of $61.2B against $12.8B for Assurant, Inc., while their respective market capitalizations stand at $451.5B and $10.5B. AbbVie Inc. is headquartered in United States and Assurant, Inc. operates from United States, and those different home markets shape how each company competes.
AbbVie Inc.: AbbVie began as the separated pharmaceutical arm of Abbott Laboratories and became one of the world's largest biopharma companies by using Humira cash flow to build a broader portfolio. The company now presents itself as a diversified specialty-medicine platform rather than a single-product story.
Assurant, Inc.: Assurant makes money through insurance premiums, service-contract fees, claims administration, partner distribution, and specialty protection programs embedded through mobile carriers, lenders, retailers, property managers, auto dealers, and other brands.
Business Models: How AbbVie Inc. and Assurant, Inc. Make Money
AbbVie Inc. and Assurant, Inc. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between AbbVie Inc. and Assurant, Inc..
AbbVie Inc. business model: AbbVie earns revenue from patented and specialty medicines sold globally through healthcare systems, insurers, distributors, specialists, hospitals, and aesthetics providers. Immunology is the largest segment, supported by neuroscience, oncology, aesthetics, eye care, and other therapeutics.
Assurant, Inc. business model: The economics of this segment are driven by massive volume and microscopic margins; Assurant typically charges the end consumer between $8 and $15 per month for a device protection plan, a fee that is automatically billed by the wireless carrier (such as T-Mobile, AT&T, or Verizon) or the device manufacturer. In exchange for distributing the product and handling the billing, the carrier or manufacturer retains a commission ranging from 20% to 40% of the premium, leaving Assurant with the remaining 60% to 80% to fund claims, administrative costs, and underwriting profit. The loss ratio in this segment is meticulously managed at approximately 35%, meaning that for every $100 in net earned premium, Assurant pays out only $35 in claims for cracked screens, water damage, and lost devices. The remaining $65 is allocated to technology infrastructure, third-party repair network fees, carrier commissions, and profit. However, the regulatory risk is immense, as state insurance commissioners and the Consumer Financial Protection Bureau (CFPB) strictly scrutinize LPI practices to prevent predatory pricing and ensure that borrowers are properly notified before a policy is forced. The dealership retains a commission of 30% to 50% for selling the product, and remits the remaining premium to Assurant. This segment operates as a cross-sell engine, leveraging Assurant's existing relationships with banks and credit unions to offer niche insurance products that enhance the institution's customer retention and generate fee income. Asurion's scale allows it to negotiate aggressive commission rates with carriers and invest heavily in proprietary repair technologies, creating a fierce duopoly where the two companies constantly battle for exclusive carrier contracts and market share. The competition in this segment is driven by the commission rates offered to dealerships; because the dealer retains a significant portion of the VSC premium, they are highly incentivized to sell the product from the administrator that offers the highest commission or the most lucrative profit-sharing arrangement. Assurant must continuously balance its underwriting discipline with the need to offer competitive commission structures to retain its exclusive partnerships with giants like CarMax and Carvana. The rise of fintech companies and insurtech startups that are attempting to reshape the traditional warranty model by offering on-demand, subscription-based vehicle protection poses a long-term threat to the fixed-term VSC model that Assurant relies on. The expense ratio, which measures the cost of commissions, administrative overhead, and technology infrastructure relative to earned premiums, stood at 40.0%, a slight increase from the prior year driven by the heavy investment in AI-driven claims automation and the expansion of the global reverse logistics network. Assurant's balance sheet remains exceptionally strong, with statutory capital ratios well above the regulatory minimums required by the National Association of Insurance Commissioners (NAIC), providing the company with the financial flexibility to absorb potential shocks, such as a severe hurricane season or a spike in automotive repair costs, while still meeting its obligations to policyholders and distribution partners. Concurrently, the Global Housing segment faces intense regulatory headwinds from state insurance commissioners and the Consumer Financial Protection Bureau (CFPB), who view lender-placed insurance as a potentially predatory practice that exploits vulnerable homeowners. Regulators have mandated stricter notification requirements, capped the premiums that can be charged, and required insurers to provide more transparent reporting on the commissions paid to mortgage servicers. Yet if the frequency of claims or the severity of repair costs outpaces Assurant's ability to adjust the pricing of new VSCs, the segment's underwriting margin will deteriorate. The company's digital transformation strategy involves the deployment of artificial intelligence and machine learning across its entire value chain, from underwriting and pricing to claims processing and customer service. The company is also exploring strategic partnerships with proptech companies and smart home device manufacturers to integrate real-time property monitoring data into its underwriting models, allowing it to offer more accurate pricing and incentivize homeowners to adopt risk-mitigating technologies.
Competitive Advantage: AbbVie Inc. vs Assurant, Inc.
The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of AbbVie Inc. stack up against those of Assurant, Inc..
AbbVie Inc. competitive advantage: AbbVie's advantage comes from deep immunology scale, specialist sales relationships, strong cash flow, global clinical and regulatory capabilities, and a portfolio led by Skyrizi, Rinvoq, Botox, Vraylar, Imbruvica, Venclexta, and Elahere.
Assurant, Inc. competitive advantage: By using its deep, API-level integrations with the world's largest distribution partners, its proprietary actuarial data, and its massive scale, Assurant is well-positioned to navigate the complex regulatory and technological challenges of the coming decades, continuing to generate massive free cash flow and deliver attractive returns to its shareholders while fulfilling its mission of providing critical financial protection to millions of consumers worldwide. Assurant's advantage in this segment lies in its ability to cross-sell niche products, such as pet insurance and identity theft protection, through its existing relationships with financial institutions, but it lacks the brand equity of Aflac to compete effectively in the direct-to-consumer or large employer markets. Despite these intense competitive pressures across all four segments, Assurant's unique combination of technological integration, logistical scale, and actuarial precision provides a level of defensibility that allows it to maintain its leadership position and generate consistent, attractive returns for its shareholders, even as the competitive landscape becomes increasingly crowded and complex. Assurant's single most unreplicable moat is its deep, API-level integration into the transactional infrastructure of the world's largest wireless carriers, mortgage servicers, and automotive retailers, combined with its proprietary global reverse logistics network for device refurbishment. Assurant's global reverse logistics network, which manages the retrieval, triage, repair, and redistribution of millions of damaged electronic devices annually, creates a circular economy advantage that pure-risk underwriters cannot match. In the Global Housing segment, Assurant's competitive advantage is rooted in its unparalleled actuarial data and its exclusive master policyholder relationships with the largest mortgage servicers in the United States. This data advantage enables Assurant to accurately predict which loans are most likely to experience an insurance lapse, allowing the company to proactively intervene and reinstate voluntary coverage before a more expensive LPI policy is triggered, a capability that reduces regulatory risk and improves the loss ratio for both Assurant and its servicer partners. In the Global Preowned Auto segment, Assurant's moat is built on its exclusive, long-term partnerships with the largest automotive retailers, including CarMax and Carvana, and its proprietary underwriting algorithms that use real-time vehicle diagnostic data. This combination of technological integration, logistical scale, actuarial precision, and financial strength creates a formidable barrier to entry, allowing Assurant to maintain its dominant market share across multiple specialty insurance niches while operating with an expense ratio that is significantly lower than its peers.
Growth Strategy: Where AbbVie Inc. and Assurant, Inc. Are Headed
Future prospects matter as much as current results. The growth strategies below explain how AbbVie Inc. and Assurant, Inc. each plan to expand from here.
AbbVie Inc. growth strategy: AbbVie's growth strategy is to expand indications for Skyrizi and Rinvoq, defend Botox and aesthetics, invest in neuroscience and oncology, use targeted acquisitions to add late-stage assets, and maintain disciplined cash generation after Humira's decline.
Assurant, Inc. growth strategy: Assurant's growth strategy centers on partner-led distribution, mobile device protection, housing insurance, vehicle protection, claims operations, connected-device logistics, and selective expansion into adjacent protection programs such as home warranty.
Financial Picture: AbbVie Inc. vs Assurant, Inc.
A closer look at the financial trajectory of AbbVie Inc. and Assurant, Inc. rounds out the comparison.
AbbVie Inc.: AbbVie generated $61.160 billion in FY2025 net revenue, up 8.6% on a reported basis, with immunology contributing $30.406 billion. Q1 2026 revenue reached $15.002 billion, showing continued growth after the Humira patent cliff as Skyrizi and Rinvoq scaled.
Assurant, Inc.: Assurant reported $12.8B in FY2025 total revenue and $872.7M in GAAP net income. Net earned premiums, fees, and other income from Global Lifestyle and Global Housing reached $12.35B, up 8% from 2024. The company also reported adjusted EBITDA excluding reportable catastrophes of $1.73B.
Company-Specific SWOT Notes
AbbVie Inc.
Skyrizi generated $17.
AbbVie is no longer only an immunology company.
Humira's decline shows the core weakness of the pharmaceutical model: even extraordinary blockbusters eventually lose exclusivity.
Even after diversification, AbbVie's earnings power is tied heavily to Skyrizi, Rinvoq, Botox, Vraylar, Imbruvica, Venclexta, and Humira.
Cerevel adds neuroscience pipeline depth, while ImmunoGen adds Elahere and antibody-drug conjugate expertise.
Rinvoq belongs to the JAK inhibitor class, which carries FDA boxed-warning scrutiny, while Humira faces biosimilars and other franchises face competitors from Johnson & Johnson, Eli Lilly, Pfizer, Merck, Amgen, Roche, Novartis, Sanofi, and AstraZeneca.
Assurant, Inc.
Assurant’s underwriting engine and claims processing systems are embedded directly into the billing and customer service infrastructure of the world’s largest wireless carriers and mortgage servicers, creating switching costs that are virtually insurmountable
By leveraging its deep, API-level integrations with the world's largest distribution partners, its proprietary actuarial data, and its massive scale, Assurant is well-positioned to navigate the complex regulatory and technological challenges of the coming deca
The Global Housing segment faces intense regulatory scrutiny from the CFPB and state insurance commissioners regarding LPI practices, creating perpetual compliance costs and the risk of premium caps that could compress segment margins.
By expanding its global reverse logistics network to manage the repair and resale of refurbished devices, Assurant can capture the residual value of damaged electronics, effectively subsidizing claims costs and generating a new, high-margin revenue stream.
Original equipment manufacturers like Apple and Samsung are aggressively bundling proprietary protection plans directly into the device purchase experience, threatening to relegate Assurant to a back-office administrative role and compressing underwriting marg
Head-to-Head Scorecard
| Category | Winner | Why |
|---|---|---|
| Revenue Scale | AbbVie Inc. | AbbVie Inc. reports the larger revenue base ($61.2B), which serves as a core operational scale signal. |
| Profitability Potential | Comparable | Both organizations prioritize market penetration or are at equivalent reporting tiers. |
| Company Age | Assurant, Inc. | Founded in 2013 vs 1892. The earlier pioneer typically commands longer historical institutional legacy. |
| Innovation Moat | AbbVie Inc. | Higher aggregate count of major acquisitions and key R&D releases indicates a more active technology absorption velocity. |
| Scale (Employees) | AbbVie Inc. | A significantly larger reported workforce supports enhanced global distribution capability. |
| Market Cap | AbbVie Inc. | Higher public valuation denotes greater forward-looking investor conviction in earnings potential. |
| Future Outlook | Tied | Strategic auditing assesses that both maintain defensive leadership vectors within their core market clusters. |
Who Wins Each Category?
AbbVie Inc. reports the larger revenue base ($61.2B), which serves as a core operational scale signal.
Both organizations prioritize market penetration or are at equivalent reporting tiers.
Founded in 2013 vs 1892. The earlier pioneer typically commands longer historical institutional legacy.
Higher aggregate count of major acquisitions and key R&D releases indicates a more active technology absorption velocity.
A significantly larger reported workforce supports enhanced global distribution capability.
Who Wins: AbbVie Inc. or Assurant, Inc.?
Reviewed by Swet Parvadiya, May 2026 - Author Profile
Our analysts compile business strategy profiles from public financial filings, press releases, and analyst reports. Each profile is reviewed for accuracy before publication by our editorial desk and updated on a rolling basis.
Frequently Asked Questions: AbbVie Inc. vs Assurant, Inc.
Is AbbVie Inc. better than Assurant, Inc.?
Verdict: Between AbbVie Inc. and Assurant, Inc., AbbVie Inc. is the stronger overall option based on higher annual revenue. The decision still depends on which factors matter most for your needs, but on the weight of the evidence above, AbbVie Inc. comes out ahead in this AbbVie Inc. vs Assurant, Inc. comparison.
Who earns more — AbbVie Inc. or Assurant, Inc.?
AbbVie Inc. earns more with $61.2B in annual revenue versus Assurant, Inc.'s $12.8B. AbbVie Inc. leads on total revenue based on latest verified figures.
Which company has higher revenue — AbbVie Inc. or Assurant, Inc.?
AbbVie Inc. reported $61.2B, while Assurant, Inc. reported $12.8B. The revenue leader is AbbVie Inc. based on latest verified figures.
AbbVie Inc. revenue vs Assurant, Inc. revenue — which is higher?
AbbVie Inc. revenue: $61.2B. Assurant, Inc. revenue: $12.8B. AbbVie Inc. has the larger revenue base of the two companies.
Sources & References
- SEC EDGAR: AbbVie Inc. Annual Filings (10-K, 8-K)
- AbbVie Inc. Corporate Website
- AbbVie Inc. Annual Report 2025 - Revenue and Financial Data
- news.abbvie.com
- prnewswire.com
- abbvie.com
- news.abbvie.com
- investors.abbvie.com
- news.abbvie.com
- news.abbvie.com
- news.abbvie.com
- investors.abbvie.com
- cms.gov
- fda.gov
- SEC EDGAR: Assurant, Inc. Annual Filings (10-K, 8-K)
- Assurant, Inc. Corporate Website
- Assurant, Inc. Annual Report 2025 - Revenue and Financial Data
- sec.gov
- sec.gov
- ir.assurant.com
- data.sec.gov